Marlborough-based Ocata Therapeutics is moving forward on research that could lead to a steady supply of tissue to treat diseased and injured corneas.
The research being conducted with collaborators at the University of Miami, University of California, San Diego and Stanford University focuses on the use of a replenishable stem cell source to manufacture cornea cells for transplant into patients. Early research in this area has now been published in the journal PLOS One.
The two-step method laid out in the research creates cells that do not rely on donor corneas, according to a release from Ocata, but rather uses a single stem cell source. This could be an answer to the shortage of transplantable cornea tissue worldwide, according to the company.
